Cancers & treatments·Regimen libraryLater line

177Lu-PSMA-617

Checked 2026-09-09

PSMA PET-positive metastatic castration-resistant prostate cancer after an AR-pathway inhibitor (PSMAfore) and, in VISION, after taxane

One cycle

every 42 days × 6 · about 36 weeks in total

42-day cycle × 6 (about 36 weeks)Intravenous

Components

Drug	Dose	Route	Days	Note
Lutetium-177 vipivotide tetraxetan Radioligand therapy (beta)	7.4 GBq	IV	D1

Cycles

42-day cycle

Emetogenicity

Low (10-30%)

G-CSF

Not routine

Notes

Dry mouth, nausea, fatigue and cytopenias; renal function and marrow reserve are checked before each cycle.

Used in

Prostate cancer

Trials

VISION PSMAfore PSMAddition

Products

Gallium-68 gozetotide (PSMA-11)Piflufolastat F-18 / Pylarify TruVuLutetium-177 vipivotide tetraxetan

Source

VISION, NEJM 2021

Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.

Other regimens for these cancers

Docetaxel + prednisone

Metastatic hormone-sensitive (with ADT, 6 cycles: CHAARTED, ARASENS) or castration-resistant prostate cancer

every 21 days × 6

Cabazitaxel + prednisone

Metastatic castration-resistant prostate cancer after docetaxel and an AR-pathway inhibitor

every 21 days

Abiraterone + prednisone with ADT

High-risk metastatic hormone-sensitive (LATITUDE, STAMPEDE) or castration-resistant prostate cancer

every 28 days

Olaparib maintenance

Newly diagnosed BRCA-mutant advanced ovarian cancer after platinum response (2 years); recurrent platinum-sensitive disease; BRCA/HRR-mutant prostate; germline BRCA pancreatic after platinum

every 28 days × 2

All regimens BEP →